Cellectis Aktie

3,24 EUR +0,04 EUR +1,25 %

17.02.2026

BMN

3,93 USD +0,16 USD +4,24 %

17.02.2026

BTT

Cellectis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Div. Rendite0,00%

WKNA14QZE

ISINUS15117K1034

SymbolCLLS

Cellectis Aktien News

Sortieren:Datum Meistgelesen

06.05.24GlobeNewswireCellectis Announces Completion of the Additional Equity Investment by AstraZeneca

02.05.24GlobeNewswireCellectis Appoints Arthur Stril as Interim Chief Financial Officer

29.04.24GlobeNewswireCellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

22.04.24GlobeNewswireCellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

10.04.24GlobeNewswireCellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

08.04.24GlobeNewswireCellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

04.04.24GlobeNewswireMonthly information on share capital and company voting rights

04.03.24GlobeNewswireMonthly information on share capital and company voting rights

02.02.24GlobeNewswireMonthly information on share capital and company voting rights

16.01.24GlobeNewswireCellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

08.01.24GlobeNewswireMonthly information on share capital and company voting rights

22.12.23GlobeNewswireCellectis Reports Results from Shareholders Meeting Held on December 22, 2023

01.12.23GlobeNewswireMonthly information on share capital and company voting rights

17.11.23GlobeNewswireCellectis’ Shareholders Meeting to be Held on December 22, 2023

15.11.23GlobeNewswireCellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

06.11.23GlobeNewswireCellectis Reports Financial Results for Third Quarter and First Nine Months 2023

03.11.23GlobeNewswireMonthly information on share capital and company voting rights

02.11.23GlobeNewswireCellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting

01.11.23GlobeNewswireCellectis to Report Third Quarter 2023 Financial Results on November 6, 2023

01.11.23GlobeNewswireCellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca

31.10.23GlobeNewswireCellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

24.10.23GlobeNewswireCellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress

03.10.23GlobeNewswireMonthly information on share capital and company voting rights

27.09.23GlobeNewswireCellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

05.09.23GlobeNewswireMonthly information on share capital and company voting rights

07.08.23GlobeNewswireCellectis Provides Full Report for Second Quarter 2023 Financial Results

01.08.23GlobeNewswireMonthly information on share capital and company voting rights

27.07.23GlobeNewswireCellectis to Report Second Quarter 2023 Financial Results on August 3, 2023

12.07.23GlobeNewswireCellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors

05.07.23GlobeNewswireMonthly information on share capital and company voting rights

28.06.23GlobeNewswireCellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023

13.06.23GlobeNewswireMonthly information on share capital and company voting rights

09.06.23GlobeNewswireCellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023

05.06.23GlobeNewswireCellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event

31.05.23GlobeNewswireCellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies

17.05.23GlobeNewswireCellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023

12.05.23GlobeNewswireCellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors

11.05.23GlobeNewswireCellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

10.05.23GlobeNewswireMonthly information on share capital and company voting rights

04.05.23GlobeNewswireCellectis Provides Business Update and Reports Financial Results for First Quarter 2023

Cellectis News

Cellectis News: auf dieser Seite finden Sie alle Cellectis News und Nachrichten zur Cellectis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Cellectis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Cellectis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.